Speaker illustration

Doctor Senthil Selvaraj

Duke University School of Medicine, Durham (United States of America)

Dr. Selvaraj is a physician-scientist and HF cardiologist who combines cardiovascular metabolism and clinical trials in HF. He completed undergraduate/medical school training in the Honors Program of Medical Education at Northwestern University. Here, he also received Master's training in bioethics. At the Brigham and Women's Hospital, he completed residency, chief residency, and a preventive cardiology fellowship. At Penn, he has completed cardiology fellowship with advanced training in echocardiography and nuclear cardiology. He is completing advanced HF/transplant currently at Penn where he also received a Master's degree in translational research. His research program, supported by the AHA, NIH, DDCF, and several others, focuses on the cardiometabolic origins of HF and leverages targeted metabolic interventions to improve HF-related pathobiologies.

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF

Event: Heart Failure 2022

Topic: Pharmacotherapy

Session: Registries and Trial updates I

Thumbnail

Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Pharmacotherapy

Session: Novel Pharmacotherapies and Surgical Procedures for Heart Failure: How To Succeed?

Thumbnail

Off hours versus on hours presentation in ST-segment elevation myocardial infarction: findings from CHAMPION PHOENIX

Event: ESC CONGRESS 2016

Topic: Infarction acute phase STEMI

Session: Time and space in acute coronary syndrome

Thumbnail

ESC 365 is supported by

logo Novo Nordisk